Sickle cell disease is caused by an autosomal recessive point mutation in the β-globin gene, leading to the substitution of a glutamic acid (a hydrophilic amino acid) with a valine (a hydrophobic amino acid) at the sixth position. This change promotes the polymerization of deoxygenated hemoglobin (HbS), causing red blood cells to deform into a sickle shape, leading to vaso-occlusion and hemolysis.

Vitamin B12 is a cofactor for the enzyme methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA. In B12 deficiency, methylmalonyl-CoA accumulates, leading to the incorporation of abnormal fatty acids into neuronal lipids. This disrupts the structure and maintenance of myelin sheaths, particularly in the dorsal and lateral spinal columns, causing the subacute combined degeneration seen in these patients. This results in deficits in proprioception, vibration sense, and motor pathways.

This patient's presentation of mucocutaneous bleeding with an autosomal dominant inheritance pattern is classic for von Willebrand disease (vWD). Von Willebrand factor (vWF) has two main functions in hemostasis: it mediates the adhesion of platelets to injured endothelium by binding to glycoprotein Ib, and it serves as a carrier protein for Factor VIII, protecting it from degradation. The deficiency of vWF leads to impaired platelet plug formation and a secondary decrease in Factor VIII levels, which can mildly prolong the aPTT.

The patient's presentation of acute onset, isolated severe thrombocytopenia following a recent viral illness is characteristic of Immune Thrombocytopenic Purpura (ITP). The underlying pathophysiology involves the production of IgG autoantibodies that target platelet membrane glycoproteins, most commonly GpIIb/IIIa. These antibody-coated platelets are then cleared from circulation by phagocytes in the spleen, leading to thrombocytopenia.

This patient is experiencing an acute hemolytic episode triggered by an oxidative stressor (sulfonamide drug), which is classic for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. G6PD is the rate-limiting enzyme in the pentose phosphate pathway, which is the sole source of NADPH in red blood cells. NADPH is required by glutathione reductase to regenerate reduced glutathione (GSH). GSH is essential for detoxifying reactive oxygen species. Without adequate G6PD activity, RBCs cannot produce sufficient NADPH to maintain GSH levels, making them highly susceptible to oxidative damage, which leads to hemolysis and the formation of Heinz bodies (denatured hemoglobin).

This patient has anemia of chronic disease (also called anemia of inflammation), secondary to her rheumatoid arthritis. Chronic inflammatory states lead to increased production of pro-inflammatory cytokines, particularly IL-6. IL-6 stimulates the liver to produce hepcidin, an acute phase reactant that acts as the central regulator of iron homeostasis. Hepcidin downregulates ferroportin on intestinal enterocytes and macrophages, which traps iron within these cells. This leads to decreased iron absorption, reduced iron release from macrophage stores, and ultimately a functional iron deficiency for erythropoiesis, resulting in the characteristic lab pattern of low serum iron, low TIBC, and high ferritin (as iron is trapped in storage).

This patient's symptoms (aquagenic pruritus, plethora, splenomegaly) and labs (erythrocytosis with suppressed EPO) are classic for polycythemia vera (PV). PV is a myeloproliferative neoplasm characterized by the overproduction of all three hematopoietic cell lines, most prominently red blood cells. Over 95% of cases are associated with a gain-of-function mutation in the JAK2 gene (V617F). JAK2 is a cytoplasmic (non-receptor) tyrosine kinase that transduces signals from the erythropoietin receptor. The mutation leads to constitutive activation of the kinase, resulting in cytokine-independent proliferation of hematopoietic precursors.

This patient's presentation is classic for β-thalassemia major (Cooley anemia). This is an autosomal recessive disorder caused by mutations that lead to absent or severely reduced synthesis of the β-globin chains of hemoglobin. Hemoglobin A (α2β2) is the major adult hemoglobin and requires β-globin chains for its synthesis. Therefore, in β-thalassemia major, there is a severe deficiency or absence of HbA. The body compensates by producing increased amounts of fetal hemoglobin (HbF, α2γ2) and HbA2 (α2δ2), which become the predominant forms of hemoglobin after birth.

This patient's presentation of a venous thromboembolism at a young age, especially in the setting of a prothrombotic state (pregnancy) and a positive family history, is highly suggestive of an inherited thrombophilia. The most common cause is Factor V Leiden, which is a point mutation in the Factor V gene. This mutation makes Factor Va resistant to cleavage and inactivation by activated Protein C. Protein C (along with its cofactor Protein S) is a natural anticoagulant that normally downregulates the coagulation cascade by inactivating Factors Va and VIIIa. Resistance to this process leads to a hypercoagulable state.

This child's presentation, including living in an old house, neurobehavioral symptoms (irritability), and microcytic anemia with basophilic stippling (the coarse blue granules), is classic for lead poisoning. Lead interferes with heme synthesis by inhibiting two key enzymes: aminolevulinate (ALA) dehydratase and ferrochelatase. Ferrochelatase is the final enzyme in the pathway, incorporating iron into protoporphyrin IX to form heme. Inhibition of these enzymes leads to a microcytic anemia (due to impaired hemoglobin production) and an accumulation of precursors like ALA and protoporphyrin.